A Phase 3 interventional study of Paliperidone palmitate and Placebo in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed at 57 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-06-17.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.
Among the 115 studies testing paliperidone in Schizophrenia, this one is the 34th largest by enrollment, is one of 8 that started in 2010, is one of 41 in phase 3, and was the 63rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
Alejandro Alva · Sites in United States
Ages 18–65
Jiangsu Province Nanjing Brain Hospital · Sites in China
Ages 18–65
Sher-E-Bangla Medical College · Sites in Bangladesh
Ages 18–60
By country, each count listing its studies:
paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 7 · Phase 3 42 · Phase 4 42
First in 2003; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 323 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 115 interventional studies. Of the 104 that completed or were terminated, 42 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 115 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 52nd largest by enrollment of the 176 interventional ones that give a count, is one of 13 that started in 2010, is one of 74 in phase 3, and was the 146th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing paliperidone in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07493551CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Bioequivalence Study of PP3M in Patients With Schizophrenia | 2026-12-31 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 115 studies testing paliperidone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as compared with placebo in the treatment of participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions [a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into the self).
This is a randomized (the study drug is assigned by chance), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect), parallel-group (comparing the response in two groups of participants receiving different treatments), fixed-dose, multi-center (when more than one hospital or medical school team work on a medical research study) study of paliperidone palmitate in participants with schizophrenia. The study will consist of 3 periods: an up to 2-week pre-observation (screening) period, a double-blind period from Day 1 (baseline) to Week 13 (end of double-blind period) assessment, and a post-observation period starting after the Week 13 assessment to Week 21. For participants who discontinue the study before the last assessment in Week 13, the post-observation period will start after the discontinuation from double-blind period assessment with follow-up visits at 4, 8, and 12 weeks after the last injection. After completion of the double-blind period (Week 13), discontinuation of double-blind period treatment or withdrawal from the study, participants may receive treatment consistent with the usual standard of care. The total duration of the study will be 21 weeks, including the double-blind and post-observation periods. Participants will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio (intramuscular injections of either paliperidone palmitate or matching placebo). Injections of paliperidone palmitate or placebo will be given at Day 1 and at Weeks 1, 5, and 9 by a study drug manager and/or injector. For those participants receiving paliperidone palmitate, the Day 1 injection will be 150 milligram equivalent (mg eq.) paliperidone palmitate, followed by 100 mg eq. injections of paliperidone palmitate at Week 1, and 75 mg eq. injections of paliperidone palmitate at Weeks 5 and 9. Participants randomly assigned to placebo will receive injections matching the paliperidone palmitate injections on the same days. Efficacy will be assessed using Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression - Severity (CGI-S). Participant's safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paliperidone palmitate
Drug: Placebo
Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.
Time frame: Baseline and Week 13 or early discontinuation
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 13 or Early Discontinuation
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.
Time frame: Baseline and Week 13 or early discontinuation
Participants With Response to the Treatment as Per PANSS Total Score.
Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.
Time frame: up to Week 13 or early discontinuation
Change From Baseline in PANSS Marder Subscale Scores at Week 13 or Early Discontinuation
The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.
Time frame: Baseline and Week 13 or early discontinuation (ED)
Change From Baseline in PANSS Negative Subscale Score at Week 13 or Early Discontinuation
Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.
Time frame: Baseline and Week 13 or early discontinuation
Change From Baseline in PANSS Positive Subscale Score at Week 13 or Early Discontinuation
Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.
Time frame: Baseline and Week 13 or early discontinuation
Change From Baseline in PANSS General Psychopathology Subscale Score at Week 13 or Early Discontinuation
General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.
Time frame: Baseline and Week 13 or early discontinuation
| Milestone | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Placebo (Post-observational) | Paliperidone Palmitate (Post-observational) |
|---|---|---|---|---|
| Started | 164 | 159 | 0 | 0 |
| Completed | 55 | 95 | 0 | 0 |
| Not completed | 109 | 64 | 0 | 0 |
| Withdrew: Adverse event | 45 | 27 | 0 | 0 |
| Withdrew: Lack of efficacy | 45 | 21 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 16 | 13 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Withdrew: Fail to meet "study population" criteria | 0 | 1 | 0 | 0 |
| Milestone | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Placebo (Post-observational) | Paliperidone Palmitate (Post-observational) |
|---|---|---|---|---|
| Started | 0 | 0 | 156 | 155 |
| Completed | 0 | 0 | 144 | 149 |
| Not completed | 0 | 0 | 12 | 6 |
| Withdrew: Other | 0 | 0 | 12 | 6 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Baseline | 83.5 ± 15.18 | 85.7 ± 14.57 |
| Change at Week 13 or Early Discontinuation | 6.9 ± 19.13 | -3.1 ± 20.32 |
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants", higher scores indicate worsening.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Baseline | 4.0 (2 to 7) | 4.0 (2 to 6) |
| Change at Week 13 or Early Discontinuation | 0.0 (-3 to 3) | 0.0 (-3 to 3) |
Participants with response were defined as those participants who shows 30 percent or more and 20 percent or more reduction in PANSS total score.
| participants | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Greater than or equal to 30 percent Improvement | 14 | 36 |
| Greater than or equal to 20 percent Improvement | 23 | 52 |
The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28, higher score indicates greater severity.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Positive symptoms: Baseline | 24.3 ± 5.56 | 24.2 ± 5.66 |
| Positive symptoms: Change at Week 13 or ED | 1.6 ± 6.06 | -1.1 ± 6.29 |
| Negative symptoms: Baseline | 21.7 ± 6.22 | 22.8 ± 6.04 |
| Negative symptoms: Change at Week 13 or ED | 0.9 ± 5.82 | -1.4 ± 5.76 |
| Disorganized thoughts: Baseline | 19.6 ± 5.13 | 20.8 ± 4.83 |
| Disorganized thoughts: Change at Week 13 or ED | 1.9 ± 5.24 | -0.6 ± 5.11 |
| Uncontrolled hostility/excitement: Baseline | 8.3 ± 3.07 | 8.6 ± 3.42 |
| Uncontrolled hostility: Change at Week 13 or ED | 1.9 ± 4.23 | 0.4 ± 4.15 |
| Anxiety/depression: Baseline | 9.5 ± 3.02 | 9.4 ± 3.14 |
| Anxiety/depression: Change at Week 13 or ED | 0.7 ± 3.27 | -0.4 ± 3.54 |
Negative Syndrome Scale (range 7-49): Sum of scores for items 1-7 in negative subscale: blunted effect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking, higher scores indicate worsening.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Baseline | 22.7 ± 6.19 | 24.0 ± 5.77 |
| Change at Week 13 or Early Discontinuation | 0.9 ± 5.54 | -1.5 ± 5.38 |
Positive Syndrome Scale (range 7-49): Sum of scores for items 1-7 in positive subscale: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility, higher scores indicate worsening.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Baseline | 19.3 ± 4.97 | 19.5 ± 5.47 |
| Change at Week 13 or Early Discontinuation | 2.2 ± 5.82 | -0.6 ± 6.19 |
General Psychopathology (range 16-112): Sum of scores for somatic concern, anxiety, guilt feelings, tension, mannerisms/posturing, depression, motor retardation, uncooperativeness, unusual thought content, disoriented, poor attention, lack of judgment/insight, disturbance of volition, poor impulse control, preoccupation, and active social avoidance, higher scores indicate worsening.
| units on a scale | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) |
|---|---|---|
| Baseline | 41.4 ± 7.97 | 42.3 ± 7.85 |
| Change at Week 13 or Early Discontinuation | 3.8 ± 10.32 | -1.0 ± 11.04 |
Collected over From signing of the informed consent until study completion.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double-blind) | — | 25/164 (15.2%) | 131/164 (79.9%) |
| Paliperidone Palmitate (Double-blind) | — | 10/159 (6.3%) | 133/159 (83.6%) |
| Placebo (Post-observational) | — | 4/156 (2.6%) | 94/156 (60.3%) |
| Paliperidone Palmitate (Post-0bservational) | — | 6/155 (3.9%) | 79/155 (51%) |
| Event | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Placebo (Post-observational) | Paliperidone Palmitate (Post-0bservational) |
|---|---|---|---|---|
| Psychiatric symptomPsychiatric disorders | 13/164 | 4/159 | 2/156 | 2/155 |
| SchizophreniaPsychiatric disorders | 3/164 | 4/159 | 2/156 | 2/155 |
| Suicide attemptPsychiatric disorders | 2/164 | 0/159 | 0/156 | 0/155 |
| Hallucination, auditoryPsychiatric disorders | 1/164 | 0/159 | 0/156 | 1/155 |
| AkathisiaNervous system disorders | 0/164 | 0/159 | 0/156 | 1/155 |
| Mental status changesPsychiatric disorders | 0/164 | 1/159 | 0/156 | 0/155 |
| ConvulsionNervous system disorders | 0/164 | 1/159 | 0/156 | 0/155 |
| Ankle fractureInjury, poisoning and procedural complications | 0/164 | 1/159 | 0/156 | 0/155 |
| DehydrationMetabolism and nutrition disorders | 1/164 | 0/159 | 0/156 | 0/155 |
| HyponatraemiaMetabolism and nutrition disorders | 1/164 | 0/159 | 0/156 | 0/155 |
| Event | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Placebo (Post-observational) | Paliperidone Palmitate (Post-0bservational) |
|---|---|---|---|---|
| Psychiatric symptomPsychiatric disorders | 33/164 | 14/159 | 4/156 | 2/155 |
| InsomniaPsychiatric disorders | 25/164 | 27/159 | 6/156 | 6/155 |
| Injection site painGeneral disorders | 11/164 | 21/159 | 1/156 | 0/155 |
| NasopharyngitisInfections and infestations | 10/164 | 20/159 | 13/156 | 13/155 |
| Extrapyramidal disorderNervous system disorders | 8/164 | 16/159 | 6/156 | 1/155 |
| ConstipationGastrointestinal disorders | 9/164 | 9/159 | 13/156 | 8/155 |
| AnxietyPsychiatric disorders | 13/164 | 10/159 | 5/156 | 1/155 |
| AkathisiaNervous system disorders | 3/164 | 8/159 | 11/156 | 5/155 |
| Upper respiratory tract infectionInfections and infestations | 7/164 | 8/159 | 4/156 | 6/155 |
| HeadacheNervous system disorders | 6/164 | 8/159 | 5/156 | 4/155 |
Safety analysis set included all randomly assigned participants who received at least 1 injection of double-blind study drug.
| Age Continuous(years) | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Total |
|---|---|---|---|
| Mean | 44.0 ± 12.41 | 45.7 ± 13.55 | 44.8 ± 12.99 |
| Sex: Female, Male(Participants) | Placebo (Double-blind) | Paliperidone Palmitate (Double-blind) | Total |
|---|---|---|---|
| Female | 81 | 58 | 139 |
| Male | 83 | 101 | 184 |
The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paliperidone